

## DAFTAR PUSTAKA

- Abbas, T. and Dutta, A. 2009. P21 in cancer: Intricate networks and multiple activities. *Nature Reviews Cancer*. **9**(6), pp.400–414.
- Adhyatmika, A., Martien, R. and Ismail, H. 2018. Preparasi Nanopartikel Senyawa Pentagamavunon-0 Menggunakan Matriks Polimer Kitosan Rantai Sedang dan Pengait Silang Natrium Tripolifosfat Melalui Mekanisme Gelasi Ionik Sebagai Kandidat Obat Antiinflamasi. *Majalah Farmaseutik*. **13**(2), p.65.
- Aftab, S., Shah, A., Nadhman, A., Kurbanoglu, S., Aysil Ozkan, S., Dionysiou, D.D., Shukla, S.S. and Aminabhavi, T.M. 2018. Nanomedicine: An effective tool in cancer therapy. *International Journal of Pharmaceutics*. **540**(1–2), pp.132–149.
- Ahmad, J., Hasnain, S.E., Siddiqui, M.A., Ahamed, M. and Musarrat, J. 2013. MicroRNA in carcinogenesis & cancer diagnostics : A new paradigm Biogenesis of miRNA. *Indian Journal of Medical Research*. **137**(4), pp.680–694.
- Amorim, M., Lobo, J., Fontes-Sousa, M., Estevão-Pereira, H., Salta, S., Lopes, P., Coimbra, N., Antunes, L., Palma de Sousa, S., Henrique, R. and Jerónimo, C. 2019. Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. *Frontiers in Genetics*. **10**(September), pp.1–16.
- Anbalagan, M. and Rowan, B.G. 2015. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. *Molecular and Cellular Endocrinology*. **418**, pp.264–272.
- Asiaf, A., Ahmad, T.S., Arjumand, W. and Zargar, M.A. 2018. MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential *In: MicroRNA and Cancer: Methods and Protocols, Methods in Molecular Biology*., pp.119–134.



Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M.

and Jadidi-Niaragh, F. 2017. Nanoparticles and targeted drug delivery in cancer therapy.

*Immunology Letters*. **190**(April), pp.64–83.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. **68**(6), pp.394–424.

Cao, Y., Tan, Y.F., Wong, Y.S., Liew, M.W.J. and Venkatraman, S. 2019. Recent advances in chitosan-based carriers for gene delivery. *Marine Drugs*. **17**(6).

Cosco, D., Cilurzo, F., Maiuolo, J., Federico, C., Di Martino, M.T., Cristiano, M.C., Tassone, P., Fresta, M. and Paolino, D. 2015. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. *Scientific Reports*. **5**(November), pp.1–11.

Denechaud, P.D., Fajas, L. and Giralt, A. 2017. E2F1, a novel regulator of metabolism. *Frontiers in Endocrinology*. **8**(NOV), pp.1–8.

Denizli, M., Aslan, B., Mangala, L.S., Jiang, D., Rodriguez-aguayo, C., Lopez-berestein, G. and Sood, A.K. 2017. Chitosan Nanoparticles for miRNA Delivery *In: RNA Nanostructures: Methods and Protocols, Methods in Molecular Biology*,.. pp.219–230.

DeSantis, C.E., Ma, J., Gaudet, M.M., Newman, L.A., Miller, K.D., Goding Sauer, A., Jemal, A. and Siegel, R.L. 2019. Breast cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*. **69**(6), pp.438–451.

Ding, Y., Shen, S.Z., Sun, H., Sun, K., Liu, F., Qi, Y. and Yan, J. 2015. Design and construction of polymerized-chitosan coated Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticles and its application for hydrophobic drug delivery. *Materials Science and Engineering C*. **48**,

Fernandez-Piñeiro, I., Badiola, I. and Sanchez, A. 2017. Nanocarriers for microRNA delivery in cancer medicine. *Biotechnology Advances*. **35**(3), pp.350–360.

Flühmann, B., Ntai, I., Borchard, G., Simoens, S. and Mühlebach, S. 2019. Nanomedicines: The magic bullets reaching their target? *European Journal of Pharmaceutical Sciences*. **128**(October 2018), pp.73–80.

Fu, S.W., Chen, L. and Man, Y.G. 2011. miRNA biomarkers in breast cancer detection and management. *Journal of Cancer*. **2**(1), pp.116–122.

Gambari, R., Brognara, E., Spandidos, D.A. and Fabbri, E. 2016. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Ew trends in the development of miRNA therapeutic strategies in oncology (Review). *International Journal of Oncology*. **49**(1), pp.5–32.

Ganjoo, R., Soni, S., Ram, V. and Verma, A. 2016. Medium molecular weight chitosan as a carrier for delivery of lincomycin hydrochloride from intra-pocket dental film: Design, development, in vitro and ex vivo characterization. *Journal of Applied Pharmaceutical Science*. **6**(10), pp.008–019.

Gaur, S., Wen, Y., Song, J.H., Parikh, N.U., Lingegowda, S., Shi, Y., Lopez-berestein, G., Frigo, D.E. and Sood, A.K. 2015. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget*. **6**(30), pp.29161–29177.

Glover, A.R., Zhao, J.T., Gill, A.J., Weiss, J., Mugridge, N., Kim, E., Feeney, A.L., Ip, J.C., Reid, G., Clarke, S., Soon, P.S.H., Robinson, B.G., Brahmhatt, H., MacDiarmid, J.A. and Sidhu, S.B. 2015. microRNA-7 as a tumor suppressor and novel therapeutic for

adrenocortical carcinoma. *Oncotarget*. **6**(34), pp.36675–36688.

Goh, J.N., Loo, S.Y., Datta, A., Siveen, K.S., Yap, W.N., Cai, W., Shin, E.M., Wang, C.,

Kim, J.E., Chan, M., Dharmarajan, A.M., Lee, A.S.G., Lobie, P.E., Yap, C.T. and

Kumar, A.P. 2016. microRNAs in breast cancer: Regulatory roles governing the

hallmarks of cancer. *Biological Reviews*. **91**(2), pp.409–428.

Hanna, J., Hossain, G.S. and Kocerha, J. 2019. The potential for microRNA therapeutics and

clinical research. *Frontiers in Genetics*. **10**(MAY).

He, C., Chen, H., Liu, Y., Li, X., Zhang, C., Qin, Q. and Pang, Q. 2020. miR-106b-5p

promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in

osteosarcoma. *Experimental and Therapeutic Medicine*. **93**(21), pp.3203–3210.

Héloïse Ragelle, Kevin Vanvarenberg, Gaëlle Vandermeulen, and V.P. 2016. Chitosan

Nanoparticles for SiRNA Delivery In Vitro *In: Methods in molecular biology (Clifton, N.J.)*, i.

den Hollander, P., Savage, M.I. and Brown, P.H. 2013. Targeted therapy for breast cancer

prevention. *Frontiers in Oncology*. **3 SEP**(September), pp.1–15.

Holliday, D.L. and Speirs, V. 2011. Choosing correct breast cancer cell line. *Breast cancer*

*research*. **13**(4), pp.1–7.

Hosseinhali, N., Aghapour, M., Duijf, P.H.G. and Baradaran, B. 2018. Treating cancer with

microRNA replacement therapy: A literature review. *Journal of Cellular Physiology*.

**233**(8), pp.5574–5588.

Howard, E.W. and Yang, X. 2018. MicroRNA Regulation in Estrogen Receptor-Positive

Breast Cancer and Endocrine Therapy. *Biological Procedures Online*. **20**(1), pp.1–19.



Hudson, R.S., Yi, M., Esposito, D., Glynn, S.A., Starks, A.M., Yang, Y., Schetter, A.J.,

Watkins, S.K., Hurwitz, A.A., Tiffany, H., Stephens, R.M., Croce, C.M. and Ambs, S.

2014. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. *Oncogene*. **32**(35), pp.4139–4147.

Ji, W., Sun, B. and Su, C. 2017. Targeting microRNAs in cancer gene therapy. *Genes*. **8**(1), pp.1–15.

Ju, H.R., Jung, U., Sonn, C.H., Yoon, S.R., Jeon, J.H., Yang, Y., Lee, K.N. and Choi, I. 2003. Aberrant signaling of TGF- $\beta$ 1 by the mutant Smad4 in gastric cancer cells. *Cancer Letters*. **196**(2), pp.197–206.

Kaabinejadian, S., Fouladdel, S., Ramezani, M. and Azizi, E. 2008. p53 expression in MCF7, T47D and MDA-MB 468 breast cancer cell lines treated with adriamycin using RT-PCR and immunocytochemistry. *Journal of Biological Sciences*. **8**(2), pp.380–385.

Kaban, K., Salva, E. and Akbuga, J. 2017. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. *Nucleic Acid Therapeutics*. **27**(1), pp.45–55.

Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P. and Starosławska, E. 2015. Breast cancer risk factors. *Przegląd Menopauzalny*. **14**(3), pp.196–202.

Katas, H. and Alpar, H.O. 2006. Development and characterisation of chitosan nanoparticles for siRNA delivery. *Journal of Controlled Release*. **115**(2), pp.216–225.

Katas, H., Raja, M.A.G. and Lam, K.L. 2013. Development of chitosan nanoparticles as a stable drug delivery system for protein/siRNA. *International Journal of Biomaterials*. **2013**.

- Laine, A. and Westermarck, J. 2014. Molecular Pathways : Harnessing E2F1 Regulation for Prosenescence Therapy in p53-Defective Cancer Cells. *Clinical Cancer Research*. **20**(14), pp.3644–3651.
- Li, Jianghua, Cai, C., Li, Jiarui, Li, Jun, Li, Jia, Sun, T., Wang, L., Wu, H. and Yu, G. 2018. Chitosan-Based Nanomaterials for Drug Delivery. *Molecules*. (23), pp.1–26.
- Li, N., Liu, Y., Miao, Y., Zhao, L., Zhou, H. and Jia, L. 2016. MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer. *IUBMB Life*. (5), pp.764–775.
- Li, N., Miao, Y., Shan, Y., Liu, B., Li, Y., Zhao, L. and Jia, L. 2017. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K / Akt pathway in breast cancer. *Cell Death and Disease*. **8**(5), pp.1–11.
- Liang, Y., Lu, J., Mo, R., He, H. and Xie, J. 2016. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer. *International Journal of Oncology*. (48), pp.1650–1658.
- Liao, X.H., Lu, D.L., Wang, N., Liu, L.Y., Wang, Y., Li, Y.Q., Yan, T.B., Sun, X.G., Hu, P. and Zhang, T.C. 2014. Estrogen receptor  $\alpha$  mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. *FEBS Journal*. **281**(3), pp.927–942.
- Lim, L.Y., Vidnovic, N., Ellisen, L.W. and Leong, C.O. 2009. Mutant p53 mediates survival of breast cancer cells. *British Journal of Cancer*. **101**(9), pp.1606–1612.
- Louie, M.C., McClellan, A., Siewit, C. and Kawabata, L. 2010. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. *Molecular Cancer Research*. **8**(3), pp.343–352.

- Lumachi, F., Brunello, A., Maruzzo, M., Basso, U. and Basso, S. 2013. Treatment of Estrogen Receptor-Positive Breast Cancer. *Current Medicinal Chemistry*. **20**(5), pp.596–604.
- Luu, H.N., Lin, H., Sørensen, K.D., Ogunwobi, O.O., Kumar, N., Chornokur, G., Phelan, C., Jones, D., Kidd, L., Batra, J., Yamoah, K., Berglund, A., Rounbehler, R.J., Yang, M., Lee, S.H., Kang, N. and Kim, S.J. 2017. miRNAs associated with prostate cancer risk and progression. *BMC Urology*. **17**(18), pp.1–18.
- Mandal, S. and Davie, J.R. 2010. Estrogen regulated expression of the p21Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells. *Journal of Cellular Physiology*. **224**(1), pp.28–32.
- Martien, R. 2009. Oral delivery of macromolecular drugs *In: Oral Delivery of Macromolecular Drugs.*, pp.1–242.
- Martien, R., K Irianto, I.D., Farida, V., Purwita Sari, D., Farmasi Universitas Gadjah Mada, F., Studi Rekayasa Biomedis, M., Pascasarjana Universitas Gadjah Mada, S., Farmasi Universitas Ahmad Dahlan, F., Studi Farmasi, P. and Kedokteran dan Ilmu Kesehatan Universitas Muhammadiyah Yogyakarta, F. 2012. Perkembangan Teknologi Nanopartikel Sebagai Sistem Penghantaran Obat Technology Developments Nanoparticles As Drug Delivery Systems. *Majalah Farmaseutik*. **8**(1), pp.133–144.
- Masoud, V. and Pagès, G. 2017. Targeted therapies in breast cancer: New challenges to fight against resistance. *World Journal of Clinical Oncology*. **8**(2), pp.120–134.
- Mavaddat, N., Antoniou, A.C., Easton, D.F. and Garcia-Closas, M. 2010. Genetic susceptibility to breast cancer. *Molecular Oncology*. **4**(3), pp.174–191.
- Mohammed, M.A., Syeda, J.T.M., Wasan, K.M. and Wasan, E.K. 2017. An Overview of

Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.

*Pharmaceutics*. **9**(53), pp.1–26.

Mollaei, H., Safaralizadeh, R. and Rostami, Z. 2019. MicroRNA replacement therapy in cancer. *Journal of Cellular Physiology*. (November 2018), pp.1–16.

Morris, G.A., Castile, J., Smith, A., Adams, G.G. and Harding, S.E. 2011. The effect of prolonged storage at different temperatures on the particle size distribution of tripolyphosphate (TPP)-chitosan nanoparticles. *Carbohydrate Polymers*. **84**(4), pp.1430–1434.

Muluhngwi, P. and Klinge, C.M. 2015. Roles for miRNAs in endocrine resistance in breast cancer. *Endocrine-Related Cancer*. **22**(5), pp.R279–R300.

Murphy, C.G. and Dickler, M.N. 2016. Endocrine resistance in hormone-responsive breast cancer: Mechanisms and therapeutic strategies. *Endocrine-Related Cancer*. **23**(8), pp.R337–R352.

Naskar, S., Koutsu, K. and Sharma, S. 2018. Chitosan-based nanoparticles as drug delivery systems : A review on two decades of research. *Journal of Drug Targeting*.

Nelson, H.D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O’Meara, E.S., Buist, D.S.M., Kerlikowske, K., van Ravesteyn, N.T., Trentham-Dietz, A., Mandelblatt, J.S. and Miglioretti, D.L. 2012. Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis a systematic review and meta-analysis. *Annals of Internal Medicine*. **156**(9), pp.635–648.

Nguyen, M.A., Wyatt, H., Susser, L., Geoffrion, M., Rasheed, A., Duchez, A.C., Cottee, M.L., Afolayan, E., Farah, E., Kahiel, Z., Cote, M., Gadde, S. and Rayner, K.J. 2019. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage

- Nigussie Mekuria, A., Degaga Abdi, A. and Mishore, K.M. 2018. MicroRNAs as a Potential Target for Cancer Therapy. *Journal of Cancer Science & Therapy*. **10**(06), pp.152–161.
- Nishioka, C., Ikezoe, T., Pan, B., Xu, K. and Yokoyama, A. 2017. MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. *Cancer Science*. **108**(4), pp.685–695.
- O'Brien, J., Hayder, H., Zayed, Y. and Peng, C. 2018. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology*. **9**(AUG), pp.1–12.
- Patra, J.K., Das, G., Fraceto, L.F., Campos, E.V.R., Rodriguez-Torres, M.D.P., Acosta-Torres, L.S., Diaz-Torres, L.A., Grillo, R., Swamy, M.K., Sharma, S., Habtemariam, S. and Shin, H.S. 2018. Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology*. **16**(1), pp.1–33.
- Peng, B., Chen, Y. and Leong, K.W. 2015. MicroRNA delivery for regenerative medicine. *Advanced Drug Delivery Reviews*. **88**, pp.108–122.
- Petrocca, F., Visone, R., Onelli, M.R., Shah, M.H., Nicoloso, M.S., de Martino, I., Iliopoulos, D., Pillozzi, E., Liu, C.G., Negrini, M., Cavazzini, L., Volinia, S., Alder, H., Ruco, L.P., Baldassarre, G., Croce, C.M. and Vecchione, A. 2008. E2F1-Regulated MicroRNAs Impair TGF $\beta$ -Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. *Cancer Cell*. **13**(3), pp.272–286.
- Rahiemna, A., Megafitrah, M., Ramadhani, P., Mustikawaty, A. and Martien, R. 2011. Formulasi nanopartikel kitosan-PGV- Dengan Metode Ionic Gelasi. *Jurnal Saintifika Gadjah Mada*. **3**(2011), pp.17–22.

Robertson, B., Dalby, A.B., Karpilow, J., Khvorova, A., Leake, D. and Vermeulen, A. 2010.

Specificity and functionality of microRNA inhibitors. *Silence*. **1**(1), pp.1–11.

Rosenholm, J.M., Sahlgren, C. and Lindén, M. 2010. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles - Opportunities & challenges.

*Nanoscale*. **2**(10), pp.1870–1883.

Santos-Carballal, B., Aaldering, L.J., Ritzefeld, M., Pereira, S. and Sewald, N. 2015.

Physicochemical and biological characterization of chitosan- microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Nature Publishing Group*. (July), pp.1–15.

Sivoňová, M.K., Vilčková, M., Kliment, J.Á.N., Mahmood, S., Jurečková, J., Dušenková,

S., Waczulíková, I., Slezák, P. and Dobrota, D. 2015. Association of p53 and p21 polymorphisms with prostate cancer. *Biomedical Reports*. (3), pp.707–714.

Sreeram, K.J., Nidhin, M., Indumathy, R. and Nair, B.U. 2008. Synthesis of iron oxide

nanoparticles of narrow size distribution on polysaccharide templates. *Bulletin of Materials Science*. **31**(1), pp.93–96.

Stender, J.D., Frasor, J., Komm, B., Chang, K.C.N., Kraus, W.L. and Katzenellenbogen, B.S.

2007. Estrogen-regulated gene networks in human breast cancer cells: Involvement of E2F1 in the regulation of cell proliferation. *Molecular Endocrinology*. **21**(9), pp.2112–2123.

Sun, Y.S., Zhao, Z., Yang, Z.N., Xu, F., Lu, H.J., Zhu, Z.Y., Shi, W., Jiang, J., Yao, P.P. and

Zhu, H.P. 2017. Risk factors and preventions of breast cancer. *International Journal of Biological Sciences*. **13**(11), pp.1387–1397.

Tan, G., Tang, X. and Tang, F. 2014. The role of microRNAs in nasopharyngeal carcinoma.

Tolosa, L., Donato, M.T. and José Gómez, M.-L. 2015. General Cytotoxicity Assessment by Means of the MTT Assay *In: Methods in molecular biology (Clifton, N.J.)*, pp.1–390.

Villegas-Peralta, Y., López-Cervantes, J., Madera Santana, T.J., Sánchez-Duarte, R.G., Sánchez-Machado, D.I., Martínez-Macías, M. del R. and Correa-Murrieta, M.A. 2020. Impact of the molecular weight on the size of chitosan nanoparticles: characterization and its solid-state application. *Polymer Bulletin*. (0123456789).

Wang, Y., Wu, S., Jiang, B., Yin, F., Zheng, S. and Hou, S. 2015. Role of MicroRNAs in Prostate Cancer Pathogenesis. *Clinical Genitourinary Cancer*. **13**(4), pp.261–270.

Weeks, R.L. 2010. *E2F1 And Tumor Suppression : The Role of p21, miRNAs, and The DNA Damage Response*.

Wei, C.Y., Tan, Q.X., Zhu, X., Qin, Q.H., Zhu, F.B., Mo, Q.G. and Yang, W.P. 2015. Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. *International Journal of Clinical and Experimental Pathology*. **8**(11), pp.14619–14629.

Wei, K., Pan, C., Yao, G., Liu, B., Ma, T., Xia, Y., Jiang, W., Chen, L. and Chen, Y. 2017. MiR-106b-5p Promotes Proliferation and Inhibits Apoptosis by Regulating BTG3 in Non-Small Cell Lung Cancer. *Cellular Physiology and Biochemistry*. (44), pp.1545–1558.

Weng, W., Xu, M., Wang, Q., Tan, C., Sun, H. and Huang, D. 2018. miR-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA.

Wicki, A., Witzigmann, D., Balasubramanian, V. and Huwyler, J. 2015. Nanomedicine in

cancer therapy: Challenges, opportunities, and clinical applications. *Journal of*

*Controlled Release*. **200**, pp.138–157.

Williams, C. and Lin, C.Y. 2013. Oestrogen receptors in breast cancer: Basic mechanisms and clinical implications. *Ecancermedicalscience*. **7**(1), pp.1–12.

Winarti, L., Martien, R. and Siswindari 2011. Formulation of nanoparticles from short chain chitosan as gene delivery system and transfection against T47D cell line Formulasi nanopartikel menggunakan kitosan rantai. *Majalah Farmasi Indonesia*. **22**(3), pp.204–211.

Xu, J., Chen, Y., Huo, D., Khramtsov, A., Khramtsova, G., Zhang, C., Goss, K.H. and Olopade, O.I. 2016.  $\beta$ -catenin regulates c-Myc and CDKN1A expression in breast cancer cells. *Molecular Carcinogenesis*. **55**(5), pp.431–439.

Xu, X., Ho, W., Zhang, X., Bertrand, N. and Farokhzad, O. 2015. Cancer nanomedicine: From targeted delivery to combination therapy. *Trends in Molecular Medicine*. **21**(4), pp.223–232.

Yadav, S. and Couch, F.J. 2019. Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. *American Society of Clinical Oncology Educational Book*. (39), pp.61–74.

Yang, H.C. and Hon, M.H. 2009. The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. *Microchemical Journal*. **92**(1), pp.87–91.

Ysrafil 2019. *Efek Sitotoksitas Sediaan Nanopartikel Kitosan Berbasis microRNA Terhadap Kultur Cell Line Kanker Ovarium SCO3*. Universitas Gadjah Mada.



Yu, S., Kim, T., Yoo, K.H. and Kang, K. 2017. The T47D cell line is an ideal experimental

model to elucidate the progesterone-specific effects of a luminal A subtype of breast

cancer. *Biochemical and Biophysical Research Communications*. **486**(3), pp.752–758.

Zhang, X., Liu, F. and Wang, W. 2010. Coordination between Cell Cycle Progression and

Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA. *The Journal of*

*Biological Chemistry*. **285**(41), pp.31571–31580.